Annovis Bio, Inc. key statistics and ratios

In fiscal 2022, Annovis Bio, Inc. had return on equity of -69.6%, debt equal to 0.0% of equity and a current ratio of 4.68. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Annovis Bio, Inc.: financial ratios, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Return on equity	—	—	−55.7%	−69.6%	—	—	—	—
Return on assets	−88.7%	−118.3%	−53.5%	−61.8%	−243.1%	−203.8%	−164.8%	−229.7%
Current ratio	0.37	14.04	30.54	4.68	2.39	—	—	—
Debt to equity	—	—	0.0%	0.0%	—	0.0%	0.0%	—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Annovis Bio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Annovis Bio, Inc.